Results 71 to 80 of about 61,476 (246)
A glycolysis‐driven epigenetic switch promotes therapy resistance in meningioma. Increased lactate production enhances histone H3K27 lactylation, which activates PROS1 secretion. Secreted PROS1 engages TYRO3 signaling to degrade the senescence regulator CARF, allowing cancer cells to escape growth arrest.
Zhuohang Wang +12 more
wiley +1 more source
Zinc transporter SLC39A14 sustains intracellular Zn2+ levels to activate SIRT3‑dependent ANXA2 deacetylation at K302. This modification weakens ANXA2‑mTOR binding and releases autophagic‑flux suppression in nucleus pulposus cells. Dysregulated Zn2+ homeostasis disrupts this axis to drive intervertebral disc degeneration.
Yuxin Jin +23 more
wiley +1 more source
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression
Genetic alterations in the INK4a/ARF (or CDKN2A) locus have been reported in many cancer types, including melanoma; head and neck squamous cell carcinomas; lung, breast, and pancreatic cancers.
Zizhen Ming, Su Yin Lim, Helen Rizos
doaj +1 more source
The genomic map covers about 55 kb around CDKN2A according to Ensemble [59]. CDKN2A/B is located at chromosome 9p21 and their RNA products are encoded by the reverse strand.
Yu-Tsueng Liu (25268) +1 more
core +1 more source
AARS2‐SIRT5‐Driven DLD K445 Lactylation Promotes Cuproptosis Resistance in Glioblastoma Stem Cells
Lactylation of DLD at K445 by AARS2 suppresses PDH complex activity and reduces DLAT lipoylation, thereby conferring cuproptosis resistance in glioblastoma stem cells. SIRT5‐mediated delactylation restores PDH function and enhances cuproptosis sensitivity.
Mingtian Ding +12 more
wiley +1 more source
Accurately identification of cyclin-dependent kinase inhibitor 2A (CDKN2A) status is of paramount important, as it has been reported as an unfavorable prognostic biomarker in diffuse gliomas, both IDH-mutant and IDH-wild type.
Hainan Li +10 more
doaj +1 more source
IDH-mutant astrocytomas have a more indolent natural history and better prognosis than their IDH-wild type counterparts, but are still graded according to schemes developed prior to the recognition of this type of neoplasm as a distinct entity ...
Daniel F. Marker, Thomas M. Pearce
doaj +1 more source
CDKN2a (cyclin dependent kinase 2a / p16)
Review on CDKN2a (cyclin dependent kinase 2a / p16), with data on DNA, on the protein encoded, and where the gene is ...
Lemoine, A, Debuire, B, Saffroy, R
core +1 more source
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao +11 more
wiley +1 more source
The CDKN2A (p16) gene and human cancer
CDKN2A, the gene encoding the cell-cycle inhibitor p16CDKN2A, was first identified in 1994. Since then, somatic mutations have been observed in many cancers and germline alterations have been found in kindreds with familial atypical multiple mole ...
Flanders, Tamar Y. +3 more
core

